文献速递生殖医学

靶向抑制Kisspeptin神经元可逆转多囊卵巢综合征临床前小鼠模型的高雄激素血症和异常高活性LH分泌

Targeted inhibition of kisspeptin neurons reverses hyperandrogenemia and abnormal hyperactive LH secretion in a preclinical mouse model of polycystic ovary syndrome.
PubMed 文献 · Hum Reprod · 2024-01-01

研究在多囊卵巢综合征(PCOS)样小鼠模型中,通过化学遗传学方法急性和慢性抑制Kisspeptin神经元,评估对LH脉冲分泌和睾酮水平的影响。结果显示急性和慢性抑制均降低异常升高的LH脉冲分泌,慢性抑制还将高LH和睾酮水平逆转至健康对照水平并恢复生殖基因表达。

要点

  • 急性靶向抑制Kisspeptin神经元可降低PCOS小鼠异常高活性的LH脉冲分泌(P < 0.05)。
  • 慢性选择性抑制Kisspeptin神经元活性可将高LH和睾酮水平逆转至健康对照水平(P < 0.05)。
  • 慢性抑制还恢复了生殖基因表达(P < 0.05),支持Kisspeptin神经元过度活跃驱动PCOS样神经内分泌损伤的假说。

核心结论

  • 靶向抑制内源性Kisspeptin神经元活性可将PCOS小鼠模型异常高活性的LH脉冲分泌和高雄激素血症降低至健康对照水平。

研究设计与样本

  • 转基因KissCRE+/hM4Di雌鼠或同窝Cre-对照接受安慰剂或慢性来曲唑(50 µg/天)诱导PCOS样表型,随后急性(一次)或慢性(2周)暴露于氯氮平-N-氧化物以化学遗传学抑制Kisspeptin细胞(每组n = 6至10只小鼠)。

主要发现

  • PCOS小鼠急性靶向抑制Kisspeptin神经元成功降低了异常高活性的LH脉冲分泌(P < 0.05)。
  • 慢性选择性抑制Kisspeptin神经元活性将先前升高的LH和睾酮水平逆转(P < 0.05)至健康对照水平,并恢复了生殖基因表达(P < 0.05)。

临床怎么用

  • 作者认为,这些数据支持过度活跃的Kisspeptin神经元可驱动PCOS样神经内分泌损伤的假说,并可能发生于PCOS女性中。
  • 作者认为,研究结果补充了近期使用NKB受体拮抗剂降低PCOS女性LH的临床研究,并提示药理学剂量依赖性调节Kisspeptin神经元活性可能是未来临床治疗PCOS女性高雄激素血症和降低升高LH的有价值靶点。

局限性

  • 本研究未评估卵巢形态。
  • 小鼠模型可提供PCOS样条件下神经内分泌过程的机制见解,但可能无法完全模拟女性PCOS。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Do hyperactive kisspeptin neurons contribute to abnormally high LH secretion and downstream hyperandrogenemia in polycystic ovary syndrome (PCOS)-like conditions and can inhibition of kisspeptin neurons rescue such endocrine impairments? SUMMARY ANSWER: Targeted inhibition of endogenous kisspeptin neuron activity in a mouse model of PCOS reduced the abnormally hyperactive LH pulse secretion and hyperandrogenemia to healthy control levels. WHAT IS KNOWN ALREADY: PCOS is a reproductive disorder characterized by hyperandrogenemia, anovulation, and/or polycystic ovaries, along with a hallmark feature of abnormal LH hyper-pulsatility, but the mechanisms underlying the endocrine impairments remain unclear. A chronic letrozole (LET; aromatase inhibitor) mouse model recapitulates PCOS phenotypes, including polycystic ovaries, anovulation, high testosterone, and hyperactive LH pulses. LET PCOS-like females also have increased hypothalamic kisspeptin neuronal activation which may drive their hyperactive LH secretion and hyperandrogenemia, but this has not been tested. STUDY DESIGN, SIZE, DURATION: Transgenic KissCRE+/hM4Di female mice or littermates Cre- controls were treated with placebo, or chronic LET (50 µg/day) to induce a PCOS-like phenotype, followed by acute (once) or chronic (2 weeks) clozapine-N-oxide (CNO) exposure to chemogenetically inhibit kisspeptin cells (n = 6 to 10 mice/group). PARTICIPANTS/MATERIALS, SETTING, METHODS: Key endocrine measures, including in vivo LH pulse secretion patterns and circulating testosterone levels, were assessed before and after selective kisspeptin neuron inhibition and compared between PCOS groups and healthy controls. Alterations in body weights were measured and pituitary and ovarian gene expression was determined by qRT-PCR. MAIN RESULTS AND THE ROLE OF CHANCE: Acute targeted inhibition of kisspeptin neurons in PCOS mice successfully lowered the abnormally hyperactive LH pulse secretion (P < 0.05). Likewise, chronic selective suppression of kisspeptin neuron activity reversed the previously high LH and testosterone levels (P < 0.05) down to healthy control levels and rescued reproductive gene expression (P < 0. 05). LARGE SCALE DATA: N/A. LIMITATIONS, REASONS FOR CAUTION: Ovarian morphology was not assessed in this study. Additionally, mouse models can offer mechanistic insights into neuroendocrine processes in PCOS-like conditions but may not perfectly mirror PCOS in women. WIDER IMPLICATIONS OF THE FINDINGS: These data support the hypothesis that overactive kisspeptin neurons can drive neuroendocrine PCOS-like impairments, and this may occur in PCOS women. Our findings complement recent clinical investigations using NKB receptor antagonists to lower LH in PCOS women and suggest that pharmacological dose-dependent modulation of kisspeptin neuron activity may be a valuable future therapeutic target to clinically treat hyperandrogenism and lower elevated LH in PCOS women. STUDY FUNDING/COMPETING INTEREST(S): This research was supported by NIH grants R01 HD111650, R01 HD090161, R01 HD100580, P50 HD012303, R01 AG078185, and NIH R24 HD102061, and a pilot project award from the British Society for Neuroendocrinology. There are no competing interests.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Coutinho EA, Esparza LA, Rodriguez J, et al. Targeted inhibition of kisspeptin neurons reverses hyperandrogenemia and abnormal hyperactive LH secretion in a preclinical mouse model of polycystic ovary syndrome. Hum Reprod. 2024. PMID: 38978296. doi:10.1093/humrep/deae153

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。